Condition: Ovarian Cancer Recurrent · Sponsor: Merck Sharp & Dohme LLC
Researchers are looking for other ways to treat relapsed high-grade serous ovarian cancer. Relapsed means the cancer came back after treatment. High-grade means the cancer cells grow and spread quickly. Serous means the cancer started in the cells that cover the ovaries, the lining of the belly, or in the fallopian tubes. Standard treatment (usual treatment) for people with relapsed high-grade serous ovarian cancer may include: * Chemotherapy, which is a treatment that uses medicine to destroy cancer cells or stop them from growing * Targeted therapy, which is a treatment that works to control how specific types of cancer cells grow and spread Raludotatug deruxtecan (R-DXd) is a study treatment that is an antibody drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. Researchers want to know if R-DXd is safe to take with other treatments and if people tolerate them together. They also want to learn how many people have the cancer respond (gets smaller or goes away) to the treatments.
This description comes directly from the study's public registry record.
Toll Free Number · 1-888-577-8839 · Trialsites@msd.com
Always discuss trial participation with your own doctor first.
| Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0019) | New Haven, Connecticut, United States | Recruiting |
| The University of Louisville, James Graham Brown Cancer Center ( Site 0009) | Louisville, Kentucky, United States | Recruiting |
| Dana-Farber Cancer Institute ( Site 0015) | Boston, Massachusetts, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center ( Site 0003) | New York, New York, United States | Recruiting |
| OU Health University of Oklahoma Medical Center ( Site 7000) | Oklahoma City, Oklahoma, United States | Recruiting |
| Texas Oncology - DFW ( Site 8000) | Fort Worth, Texas, United States | Recruiting |
| Houston Methodist Hospital ( Site 0010) | Houston, Texas, United States | Completed |
| START Mountain Region ( Site 0008) | West Valley City, Utah, United States | Recruiting |
| University of Virginia Health System ( Site 0011) | Charlottesville, Virginia, United States | Recruiting |
| Centre Hospitalier de l'Université de Montréal ( Site 0102) | Montreal, Quebec, Canada | Recruiting |
| McGill University Health Centre ( Site 0100) | Montreal, Quebec, Canada | Recruiting |
| Rambam Health Care Campus ( Site 0202) | Haifa, Israel | Recruiting |
+ 17 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06843447